111,953 Shares in Denali Therapeutics Inc. $DNLI Acquired by Legal & General Group Plc

Legal & General Group Plc acquired a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) in the second quarter, Holdings Channel reports. The fund acquired 111,953 shares of the company’s stock, valued at approximately $2,879,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Denali Therapeutics in the second quarter worth $26,000. Headlands Technologies LLC bought a new stake in Denali Therapeutics in the second quarter valued at $26,000. Global Retirement Partners LLC acquired a new position in shares of Denali Therapeutics during the second quarter valued at $28,000. Johnson Financial Group Inc. acquired a new position in shares of Denali Therapeutics during the third quarter valued at $29,000. Finally, State of Wyoming bought a new position in shares of Denali Therapeutics during the second quarter worth about $29,000. 92.92% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the transaction, the insider owned 281,763 shares of the company’s stock, valued at approximately $7,063,798.41. This trade represents a 1.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 9.70% of the company’s stock.

Denali Therapeutics Trading Down 2.3%

NASDAQ:DNLI opened at $22.28 on Friday. Denali Therapeutics Inc. has a 1 year low of $12.58 and a 1 year high of $27.30. The stock has a market cap of $3.56 billion, a price-to-earnings ratio of -7.85 and a beta of 1.01. The business has a fifty day moving average of $24.44 and a 200-day moving average of $21.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $2.15 million. During the same quarter in the prior year, the company posted ($0.72) EPS. Equities analysts predict that Denali Therapeutics Inc. will post -2.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on DNLI shares. Wall Street Zen cut shares of Denali Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. BTIG Research reissued a “buy” rating and set a $39.00 target price on shares of Denali Therapeutics in a research note on Monday, May 11th. Wedbush restated an “outperform” rating and issued a $26.00 target price on shares of Denali Therapeutics in a research report on Monday, July 13th. Sanford C. Bernstein restated a “hold” rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. Finally, JPMorgan Chase & Co. initiated coverage on shares of Denali Therapeutics in a research note on Monday, July 13th. They issued an “overweight” rating and a $29.00 price target on the stock. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.85.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.